Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
A director at Neovacs sold 2,500,000 shares at 0.024EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS The deadline for submission of all tenders is January 10th, 2020 before 04:00pm Paris and Boston, December 6th, 2019 – 05h45pm CET - Neovacs (Euronext Growth Paris : ALNEV) announces the launch of a call for tender opened from now until January 10th, 2020 before 4:00 pm, to provide a continuation ...
APPEL D’OFFRES EN VUE D’UN PLAN DE CONTINUATION OU DE CESSION DANS LE CADRE D’UNE PROCÉDURE DE REDRESSEMENT JUDICIAIRE COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE APPEL D’OFFRES EN VUE D’UN PLAN DE CONTINUATION OU DE CESSION DANS LE CADRE D’UNE PROCÉDURE DE REDRESSEMENT JUDICIAIRE DEPÔT DES DOSSIERS AVANT LE 10 JANVIER 2020 À 16 heures Paris et Boston, le 6 décembre 2019 – 9h CET - Néovacs (Euronext Growth Paris : ALNEV) annonce le lancement d’un appel d’offres ouvert jusqu’au 10 janvier 2020 à 16h00, en vue de la présentation d’un plan de continuation par des pa...
NEOVACS REQUESTS A REORGANIZATION PROCEEDINGS OF THE COMPANY NEOVACS REQUESTS A REORGANIZATION PROCEEDINGS OF THE COMPANY Paris et Boston, November 13, 2019 – 06:00pm CET – NEOVACS (Euronext Paris: ALNEV) announces having filed today a declaration for suspension of payments and a request for the reorganization proceedings (“Redressement Judiciaire”) of the company before the Commercial Court of Paris. The employees’ representative bodies have been informed beforehand. This decision comes after acknowledging that the current amount of liabilities is higher than the realizable and availab...
NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS PRESS RELEASE PRESS RELEASE · PRESS RELEASE · PRESS RELEASE PRESS RELEASE NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS Paris and Boston, 2nd October, 2019— 9:30 p.m. CEST—NEOVACS (Euronext Paris: ALNEV, eligible for PEA-PME), a leading provider of therapeutic vaccines for the treatment of autoimmune diseases, announced today its 2019 half-year results for the period ending on 30th June 2019, approved by the Board of Directors on 2nd October 2019. Results for the first half of 2019: Cash balance improved to €3.5m compared to 3...
NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES APPOINTMENT OFVINCENT SERRA AS CHIEF EXECUTIVE OFFICER Paris & Boston, September 30, 2019 – 08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of auto-immune diseases, has today announced, the appointment of Vincent Serra, PhD, as the new Chief Executive Officer, with immediate effect, to succeed Miguel Sieler who has resigned as CEO and as a board director. Jean-Jacques Bertrand, President ...
Neovacs : 2019 Financial Calendar PRESS RELEASE PRESS RELEASE PRESS RELEASE 2019 Financial Calendar Paris, September 9, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases publishes an updated 2019 financial calendar today. Financial announcements will be published before the market opening. The expected dates are preliminary so may be subject to change. 2019 First Half Results October 2, 20192019 Annu...
NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT · PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT Paris and Boston, July 9, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, has today announced having received a first payment wit...
NEOVACS ANNOUNCES THE APPOINTMENT of Dr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE APPOINTMENT ofDr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR Paris and Boston, June 27th, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announces the appointment of Dr. Virginia Pascual as Medical and Scientific advisor. “We are delighted to welcome Dr Pascual to Neovacs. Her significant contribution to lup...
Neovacs to present the pre-clinical results of its IFNalpha Kinoid to treat type 1 diabetes - American Diabetes Association's 79th scientific sessions PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT THE PRE-CLINICAL RESULTS OF ITS IFNα KINOID TO TREAT TYPE 1 DIABETES AT THE AMERICAN DIABETES ASSOCIATION'S 79TH SCIENTIFIC SESSIONS (ADA) San Francisco, CA, USA - June 7- 11, 2019 Paris and Boston, June 5, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today ...
Neovacs to present the pre-clinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid to treat allergic Asthma PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT THE PRE-CLINICAL RESULTS OF ITS THERAPEUTIC VACCINE CANDIDATE IL-4 / IL-13 KINOID TO TREAT ALLERGIC ASTHMA « » - Girona, Spain- May 20-25, 2019« Lisbon, Portugal, June 1-5 2019 Paris and Boston, May 16, 2019 – Neovacs - 07h30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the presentation of ...
Neovacs announces the full results of its Phase IIb Clinical study of IFNalpha Kinoid in lupus - 13th International Lupus Congress 2019 PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE FULL RESULTS OF ITSPHASE IIb CLINICAL STUDY OF IFNα KINOID IN LUPUS, PRESENTED AT THE 13th INTERNATIONAL LUPUS CONGRESS 2019 Paris and Boston, April 9, 2019, 7:30 am CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases, announced that the full results of the phase IIb clinical study were present...
2019 Financial Calendar PRESS RELEASE PRESS RELEASE PRESS RELEASE 2019 Financial Calendar Paris, April 5, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases publishes an updated 2019 financial calendar today. Financial announcements will be published before the market opening. The expected dates are preliminary so may be subject to change. 2018 Annual Results March 25, 2019Annual Gener...
Neovacs announces an agreement with Biosyn GmbH to diversify its supply of Keyhole Limpet Hemocyanin (KLH) PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES AN AGREEMENT WITH BIOSYN GmbH TO DIVERSIFY ITS SUPPLY OF KEYHOLE LIMPET HEMOCYANIN (KLH) Paris et Boston, april 1st 2019 - 07h30 CEST - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces that the company has signed a new supply agreement with the German company biosyn GmbH to diversify its sourcing of KLH, one of the three ...
Neovacs reports full-year 2018 Financial results and provides corporate update RESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE KEY OPINION LEADERS VALIDATE THE THERAPEUTIC POTENTIAL OF IFNα KINOID IN LUPUS TREATMENT FOLLOWING THE RESULTS OF THE PHASE IIB CLINICAL STUDY SUCCESSFUL IN VIVO PROOF OF CONCEPT FOR ITS IL-4 / IL-13 KINOID A NEW THERAPEUTIC VACCINE TO TREAT MITE-INDUCED ASTHMA PATENT REGISTERED IN EUROPE AND THE U.S. FOR IL-4 / IL-13 KINOID, CANDIDATE VACCINE IN THE TREATMENT OF ALLERGIES FINAN...
Neovacs announces two appointments to its executive committee PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES TWO APPOINTMENTS TO ITS EXECUTIVE COMMITTEE Vincent Serra, PhD – Chief Scientific OfficerValerie Salentey, Pharm D - Head of Regulatory Affairs Paris & Boston, February 20th, 2019 - 07h30 CET - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases announces two appointments to its Executive Committee. Vincent Serra, PhD is appointed Chief Scientific Officer. W...
Néovacs : Agenda financier 2019 COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE AGENDA FINANCIER 2019 Paris et Boston, le 19 février 2019 – NÉOVACS (Euronext Growth Paris : ALNEV), leader de l’immunothérapie active pour le traitement des maladies auto-immunes, présente aujourd’hui son agenda financier 2019. Les publications financières auront lieu avant ouverture du marché. Ce calendrier est indicatif et peut être soumis à modifications. Résultats annuels 2018 mardi 16 avril 2019Assemblée générale an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.